ArticleCancer discovery2020
Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19.
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.Cancer immunology, immunotherapy : CII · 2021Trial
- Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus.World journal of diabetes · 2024Review
- Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel.Nature biomedical engineering · 2023Article
- Learning from cancer to address COVID-19.Biologia futura · 2023Review
- Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?Drug design, development and therapy · 2022Review
- COVID-19 in patients with cancer: Risks and precautions.The American journal of emergency medicine · 2021Article
- Resourcing, annotating, and analysing synthetic peptides of SARS-CoV-2 for immunopeptidomics and other immunological studies.Proteomics · 2021Article
- Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion.Seminars in immunology · 2021Review
- Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.Mayo Clinic proceedings · 2021Article
- Application of lung microphysiological systems to COVID-19 modeling and drug discovery: a review.Bio-design and manufacturing · 2021Review
- Regen med therapeutic opportunities for fighting COVID-19.Stem cells translational medicine · 2021Article
- Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.Discoveries (Craiova, Romania) · 2020Review
- Immunometabolic Status of COVID-19 Cancer Patients.Physiological reviews · 2020Review
- SARS-CoV-2 and cancer: Are they really partners in crime?Cancer treatment reviews · 2020Review
- Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?Pharmaceuticals (Basel, Switzerland) · 2020Review
- COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.European journal of heart failure · 2020Review
- IL-6: Relevance for immunopathology of SARS-CoV-2.Cytokine & growth factor reviews · 2020Review
- Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.Molecular biomedicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.